Search
UOB Kay Hian has issued a research report, reaffirming its 'Buy' rating for Ali Health (00241) and retaining a target price of HK$7.8. During the first half of fiscal year 2026, Ali Health witnessed a 17% year-on-year increase in revenue and a 38.7% surge in adjusted net profit, both surpassing market expectations. The company has reaffirmed its annual growth targets for fiscal year 2026, aiming for a 10% to 15% rise in revenue and a 20% to 30% increase in adjusted net profit. UOB Kay Hian projects that, propelled by the expansion of innovative drugs and healthcare products, enhanced synergies within Alibaba's ecosystem, and broader AI applications, Ali Health's compound annual growth rates for revenue and adjusted net profit will reach 13% and 24%, respectively, from fiscal year 2026 to 2028.
-
C114 Communication Network -
Communication Home
